SIGA (SIGA) Said Smallpox Drug Used on Human Patient
More News related to SIGA
- SIGA Reaches Next Stage in BARDA's RFP Bidding Process
- SIGA Technologies, Inc. to be Added to the Russell 3000(r) and Russell Global(r) Indices
- SIGA Completes Nonclinical Toxicology Studies Supporting Safety in Humans for ST-246(r)
- SIGA Proposal to Fund Work On Broad Spectrum Antiviral Selected for Award by Department of Defense
- SIGA Technologies, Inc. to Present At the 2009 Noble Financial Fifth Annual Equity Conference
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
SIGA Technologies, Inc. (NASDAQ: SIGA) announced this morning that a toddler who inadvertently contracted eczema vaccinatum has been treated with ST-246, SIGA's lead smallpox drug candidate, pursuant to an Emergency Investigational New Drug Application granted by the FDA, and is now improving.
The company said, due to the absence of smallpox disease in the general human population, the efficacy of ST-246 has been investigated in animals to date. However, the federal Centers for Disease Control and Prevention (CDC) was recently notified that a child had contracted eczema vaccinatum, a potentially deadly illness that can manifest with a generalized skin rash similar to smallpox, following accidental contact with an open skin lesion on a relative who had recently been vaccinated for smallpox using a live vaccinia virus vaccine. The patient developed late-stage manifestations of the disease, including hemorrhagic lesions, respiratory failure, shock and high viral loads in the blood. CDC facilitated communication between SIGA and FDA resulting in provision of ST-246 for the patient under an Emergency IND.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
